Further study to identify the mechanism by which β1-AR signal suppresses TRAF3 expression is our next subject of interest in the effort to identify reliable biomarkers and therapeutic targets for patients with MS who experienced ELT. The gene discussed is ADRB1; the disease is myeloid sarcoma.